The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris therapeutics | Common | 00461U105 | 85,243 | 2,858,569 | SH | SOLE | 0 | 0 | 2,858,569 | ||
| Advanced Accelerator Applications S.A. | Sponsored ADS | 00790T100 | 19,284 | 483,786 | SH | SOLE | 0 | 0 | 483,786 | ||
| Agile Therapeutics, Inc. | Common | 00847L100 | 4,852 | 1,513,975 | SH | SOLE | 0 | 0 | 1,513,975 | ||
| Aimmune Therapeutics, Inc. | Common | 00900T107 | 16,580 | 763,009 | SH | SOLE | 0 | 0 | 763,009 | ||
| Akari Therapeutics Plc | ADR | 00972G108 | 5,843 | 527,842 | SH | SOLE | 0 | 0 | 527,842 | ||
| Ascendis Pharma | ADR | 04351P101 | 49,471 | 1,766,832 | SH | SOLE | 0 | 0 | 1,766,832 | ||
| Aurinia Pharmaceuticals Inc. | Common | 05156V102 | 4,404 | 600,000 | SH | SOLE | 0 | 0 | 600,000 | ||
| BioPharmX Corporation | Common | 09072X101 | 6,471 | 12,814,286 | SH | SOLE | 0 | 0 | 12,814,286 | ||
| Capnia, Inc. | Common | 14066L105 | 10,434 | 14,695,264 | SH | SOLE | 14,695,264 | 0 | 0 | ||
| Capnia, Inc. | Warrant | 14066L113 | 113 | 943,858 | SH | SOLE | 943,858 | 0 | 0 | ||
| KalVista Pharmaceuticals, Inc. | Common | 483497103 | 2,346 | 300,325 | SH | SOLE | 0 | 0 | 300,325 | ||
| Codexis, Inc. | Common | 192005106 | 25,415 | 5,294,825 | SH | SOLE | 0 | 0 | 5,294,825 | ||
| CRISPR Therapeutics AG | Namen AKT | H17182108 | 3,241 | 148,878 | SH | SOLE | 0 | 0 | 148,878 | ||
| Dynavax Technologies Corporation | Common | 268158201 | 2,141 | 359,828 | SH | SOLE | 0 | 0 | 359,828 | ||
| Eiger BioPharmaceuticals | Common | 28249U105 | 20,462 | 1,787,091 | SH | SOLE | 1,787,091 | 0 | 0 | ||
| Foamix Pharmaceuticals Ltd. | Common | M46135105 | 4,232 | 855,000 | SH | SOLE | 0 | 0 | 855,000 | ||
| Nabriva Therapeutics AG | ADR | 62957M104 | 48,259 | 4,021,559 | SH | SOLE | 0 | 0 | 4,021,559 | ||
| Sierra Oncology Inc. | Common | 82640U107 | 3,731 | 2,438,270 | SH | SOLE | 0 | 0 | 2,438,270 | ||
| Regenxbio Inc. | Common | 75901B107 | 3,173 | 164,403 | SH | SOLE | 0 | 0 | 164,403 | ||
| ReVance Therapeutics, Inc. | Common | 761330109 | 1,609 | 77,373 | SH | SOLE | 0 | 0 | 77,373 | ||
| Strongbridge Biopharma plc | Ordinary Shares | G85347105 | 14,250 | 3,000,000 | SH | SOLE | 0 | 0 | 3,000,000 | ||
| Sunesis Pharmaceuticals, Inc. | Common | 867328700 | 2,050 | 500,000 | SH | SOLE | 0 | 0 | 500,000 | ||
| Trevena, Inc. | Common | 89532E109 | 6,342 | 1,728,000 | SH | SOLE | 0 | 0 | 1,728,000 | ||